Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study.
Cooper N, Jansen AJG, Bird R, Mayer J, Sholzberg M, Tarantino MD, Garg M, Ypma PF, McDonald V, Percy C, Košťál M, Goncalves I, Bogdanov LH, Gernsheimer TB, Diab R, Yao M, Daak A, Kuter DJ.
Cooper N, et al. Among authors: yao m.
Am J Hematol. 2025 Jan 22. doi: 10.1002/ajh.27539. Online ahead of print.
Am J Hematol. 2025.
PMID: 39844469